37992-Lu, Xiongbin
Faculty

Xiongbin Lu, PhD

Vera Bradley Foundation Professor of Breast Cancer Innovation

Address
R3-C218D
MMGE
IN
Indianapolis, IN

Bio

Dr. Xiongbin Lu received a Ph.D. from Shanghai Institute of Biochemistry, Chinese Academy of Sciences in 1998 (Biochemistry). He did postdoctoral studies at NIAID/NIH (1998-2000) and at Baylor College of Medicine (2000-2003) and then joined the Faculty in Baylor College of Medicine as a Research Assistant Professor. In 2007, he was recruited as a Tenure-track investigator to the Center for Colon Cancer Research at the University of South Carolina. In 2010, he moved to the Department of Cancer Biology, University of Texas MD Anderson Cancer Center and was promoted to Associate Professor in 2012. In 2017, Dr. Lu moved to Indiana University School of Medicine and was named as Vera Bradley Foundation Professor of Breast Cancer Innovation and Strategic Research Initiative Distinguished Investigator.

Dr. Lu’s research interest spans across the field of cancer research, including human cancer genomics, targeted cancer therapy and cancer immunotherapy with a focus on solid tumors. He also has a long-standing interest in biomedical engineering. Dr. Lu was inducted to the College of Fellows at American Institute for Medical and Biological Engineering in 2019. Dr. Lu has made a number of seminal discoveries that promote translational development of human cancer research. Since independent, he has trained a number of postdoctoral fellows, graduate and undergraduate students in his laboratory. Three of his postdoctoral fellows were NIH K99/R00 awardees and seven of his past trainees are now independent investigators in the US and other nations. 

 

 

Key Publications

1.     Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, He B, Miller KD, Radovich M, Schneider BP, Pahl A, Zhang X, Lu X. Targeted immunotherapy for HER2-low breast cancer with 17p loss (2021) Science Translational Medicine, 13(580):eabc6894.

2.     Sun L, Wan A, Zhou Z, Chen D, Liang H, Liu C, Yan S, Niu Y, Lin Z, Zhan S, Wang S, Bu X, He W, Lu X*, Xu A, Wan G. RNA-binding protein RALY reprograms mitochondrial metabolism via mediating miRNA processing in colorectal cancer (2020). Gut, doi: 10.1136/gutjnl-2020-320652. Online ahead of print. (*co-corresponding author).

3.     Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z, Dong T, So KM, Yu T, Li Y, Eyvani H, Colter A, Dong E, Cao S, Wang J, Schneider BP, Sandusky G, Liu Y, Zhang C, Lu X*, Zhang X (2021). MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. Journal of Clinical Investigation, 131(1):e140837 (*co-corresponding author).

4.     Van der Jeught K, Sun Y, Fang Y, Zhou Z, Jiang H, Yu T, Yang J, Kamocka MM, So KM, Li Y, Eyvani H, Sandusky GE, Frieden M, Braun H, Beyaert R, He X, Zhang X, Zhang C, Paczesny S, Lu X (2020).ST2 as checkpoint target for colorectal cancer immunotherapy. JCI Insight, 5(9). pii: 136073.

5.     Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K, Agarwal P, Zhang Y, Liu S, Zhao G, Wan J, Lu X*, He X (2019). Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nature Nanotechnology, 14(4):388-397 (*Co-corresponding author).

6.     Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, Van der Jeught K, Xu H, Zhang L, Frieden M, Wang L, Eyvani H, Sun Y, Zhao G, Zhang Y, Liu S, Wan J, Huang C, Ji G, Lu X*, He X, Zhang X (2018). Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. Nature Communications, 9(1): 4718 (*Co-corresponding author).

7.     Li Y, Liu Y, Xu H, Jiang G, Van der Jeught K, Fang Y, Zhou Z, Zhang L, Frieden M, Wang L, Luo Z, Radovich M, Schneider BP, Deng Y, Liu Y, Huang K, He B, Wang J, He X, Zhang X, Ji G, Lu X (2018). Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. Nature Communications, 9(1): 4394.

8.     Liu Y, Xu H, Van der Jeught K, Li Y, Liu S, Zhang L, Fang Y, Zhang X, Radovich M, Schneider BP, He X, Huang C, Zhang C, Wan J, Ji G, Lu X (2018). Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in human cancer. Journal of Clinical Investigation, 128(7):2951-2965.

9.     Han C, Yang L, Choi HH, Baddour J, Achreja A, Liu Y, Li Y, Li J, Wan G, Huang C, Zhang X, Nagrath D, Lu X (2016). Amplification of USP13 drives ovarian tumor metabolism. Nature Communications, 7:13525.

10.  Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X (2015). TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature, 520(7549):697-701 (highlighted in Nature Reviews Cancer, Nature Reviews Clinical Oncology and Cancer Discovery).

11.  Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu X (2014). The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Reports, 8(5):1447-60.

12.  Wan G, Hu X, Liu Y, Han C, Sood AK, Calin GA, Zhang X, Lu X (2013). A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO Journal, 32(21):2833-47.

13.  Wan G, Zhang X, Langley RR, Liu Y, Hu X, Han C, Peng G, Ellis LM, Jones SN, Lu X (2013). DNA-damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway. Cell Reports, 3(6):2100-12.

14.  Wan G, Mathur R, Hu X, Zhang X, Lu X (2011). microRNA response to DNA damage. Trends in Biochemical Sciences, 36(9):478-84.

15.  Zhang X, Berger FG, Yang J, Lu X (2011). USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO Journal, 30(11):2177-89.

16.  Zhang X, Wan G, Berger FG, He X, Lu X (2011). The ATM kinase induces microRNA biogenesis in the DNA damage response. Molecular Cell, 41:371-83 (commentary in the same issue and recommended by Faculty of 1000).

17.  Lu X*, Ma O, Nguyen T, Jones SN. Oren M, Donehower LA (2007). The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell, 12(4):342-54 (profiled in Nature Reviews Cancer, * corresponding author).

18.  Lu X, Nannenga B., Donehower LA (2005). PPM1D dephosphorylates CHK1 and p53 and abrogates cell cycle checkpoints. Genes & Development, 19(10): 1162-74 (profiled in Nature Reviews Cancer and recommended by the Faculty of 1000).

19.  Lu X, Bocangel D, Nannenga B, Yamaguchi H, Appella E, Donehower LA (2004). The p53-Induced Oncogenic Phosphatase PPM1D Interacts with Uracil DNA Glycosylase and Suppresses Base Excision Repair. Molecular Cell, 15(4): 621-34.

20.  Tyner S, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Karsenty G, Bradley A, Donehower LA (2002), p53 mutant mice that display early ageing-associated phenotypes (reported by Washington Post, New York Times, and BBC News). Nature, 415(6867): 45-53.

Titles & Appointments

  • Vera Bradley Foundation Professor of Breast Cancer Innovation
  • Professor of Medical & Molecular Genetics
  • Professor with Tenure
  • Strategic Research Initiative Distinguished Investigator
  • Education
    1998 PhD Chinese Academy of Sciences
    1993 BSC Zhejiang University
  • Research
    Human Cancer genomics, targeted cancer therapy, cancer immunotherapy and biomedical engineering.
  • Professional Organizations
    American Association for Cancer Research
    American Institute for Medical and Biological Engineering
    Indiana University School of Medicine Cancer Center
    Society of Chinese Bioscientists in America
  • Awards
    Org: American Institute for Medical and Biological Engineering
    Desc: Elected Fellow
    Scope: National
    Date: 2019-03-01
    Org: Amersham Life Sciences Inc
    Desc: Amersham Award
    Scope:
    Date:
    Org: American Federation for Aging Research
    Desc: Research Award
    Scope: National
    Date:
    Org: Center for Colon Cancer Search, University of South Carolina
    Desc: Target PI
    Scope: Regional
    Date:
    Org: American Cancer Society
    Desc: Research Award
    Scope: National
    Date:
    Org: MD Anderson Cancer Center
    Desc: Faculty Educator of the Month
    Scope: University
    Date:
    Org: MD Anderson Cancer Center
    Desc: Robert M. Chamberlain Distinguished Mentor Award Nominee
    Scope: University
    Date:
    Org: Vera Bradley Foundaton
    Desc: The Vera Bradley Foundation Chair in Breast Cancer Innovation
    Scope: University
    Date:
    Org: Indiana University School of Medicine
    Desc: Strategic Research Initiative Distinguished Investigator
    Scope: University
    Date:

Looking for patient care?

To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.

Find a doctor